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**Introduction:** Since September 2012, WHO has reported nearly 2,000 laboratory‐confirmed cases of the Middle East respiratory syndrome coronavirus (MERS‐CoV), predominantly from Saudi Arabia. There is no anti‐infective therapy approved for the infection. However, based on limited data, oral ribavirin combination with PEGylated interferon α2a injection (RIF) has been used.

**Research Question or Hypothesis:** What are the mortality rates and clinical outcomes in MERS‐CoV patients treated with RIF plus supportive care versus supportive care alone (SCA)?

**Study Design:** Retrospective historical control

**Methods:** Chart data collection for all patients diagnosed with laboratory‐confirmed MERS‐CoV infection between September 2013 and June 2017. The primary endpoint was death due to infection; secondary endpoints were the requirement for CRRT and mechanical ventilation, and changes from baseline serum creatinine (SrCr), and urea nitrogen.

**Results:** 113 patients met the study inclusion criteria; 49 of whom have received RIF and 64 SCA. In the RIF group, 24 patients have died (49%) and 23 patients (36%) in the SCA arm (p=0.182). CRRT was required in 24 RIF patients (49%) and 17 (27%) SCA patients (p=0.018). 31 patients (63%) in the RIF group required mechanical ventilation and 25 patients (39%) with SCA (p=0.014). The average rise in SrCr and urea nitrogen from baseline in the RIF arm were 2.14 mg/dl, and 42 mg/dl, respectively, while they were 1.36 and 39, respectively, in the SCA arm (p=0.050, and p=0.876, respectively).

**Conclusion:** In our study, RIF addition to supportive care was associated with inferior clinical outcomes. Larger prospective well‐designed studies are warranted to confirm these findings.
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